A novel compound which targets transcription factor STAT5 directly and selectively has been identified by an international consortium of researchers from Austria, Canada and Hungary.
The research team led by Richard Moriggl, director of the Ludwig Boltzmann Institute for Cancer Research and Professor for Functional Cancer Genomics in a joined appointment to the University of Veterinary Medicine, Vienna and Medical University Vienna chose to target the SH2 domain of STAT5, which is essential for the interactions between STAT5 proteins and their subsequent activity.
The term "hematopoietic cancer" refers to several, in most cases quite severe health conditions in which the process of blood cell production is altered. Cancers of white blood cells are characterized by enhanced proliferation and reduced differentiation and cell death in one myeloid lineage, which can promote the outgrowth of a dominant myeloid cell type. The transformation to AML is the most devastating complication experienced by patients. This type of cancer usually progresses quickly and despite considerable advances in therapeutic approaches and allogeneic hematopoietic stem cell transplantation, only 26% of patients survive longer than 5 years. These conditions are frequently caused by mutations that over-activate intracellular signalling or gene transcription. Activating mutations in the receptor FLT3 represent 30% of driver mutations in AML, which in turn activates STAT5, an important transcription factor for blood cell transformation. Targeting the mutated proteins with small molecular weight drugs is currently the leading strategy for combating cancer. However, while FLT3 inhibitors induce responses in AML-patients with FLT3 mutations initially, responses are not durable, and AML progresses in virtually all patients. New treatment strategies are therefore urgently needed to improve patient survival of this aggressive disease.
The researchers aimed at development, synthesis and preclinical testing of a new compound that targets the oncogenic functions of STAT5 proteins. Upon state-of-the-art computational molecular modelling the compound was synthesised and tested in a broad array of tests. In the study now reported in the prestigious Nature Group journal Leukemia, the compound not only binds directly to STAT5, it subsequently also disrupts STAT5 activation, nuclear translocation, and STAT5-dependent gene transcription. Bettina Wingelhofer, first author of the publication, used the compound in several leukemic cells, "we could show that our novel compound might be a good drug candidate as it impaired the proliferation of patient derived AML cell lines at low concentrations." Importantly the compound showed efficacy in freshly isolated patient samples in experiments carried out with the team of Peter Valent (Medical University Vienna), speaker of SFB-F47 and international clinical expert for AML. Initial experiments in combinations with established drugs showed that the new compound cooperatively inhibited tumour cell proliferation. Further research in cooperation with a pharmaceutical company will be required to validate this new compound class with further improvements to validate if it is indeed suitable to be used in a clinical trial.